Geneva’s biotech boom fuels demand for flexible lab space as Superlab Suisse launches Lab-as-a-Service, reshaping business strategy and operational support

Every biotech founder in Geneva faces the same practical headache: finding quality lab space that can keep up with research timelines and fundraising deadlines. The waiting lists are long, the costs are high and the flexibility simply isn’t there when you need to scale fast or pivot direction.
That challenge gets a potential solution in January 2026, when Superlab Suisse opens its fourth Swiss facility at Campus Biotech. The move completes the company’s national rollout and brings Lab-as-a-Service directly to Geneva’s growing life sciences sector.
The numbers behind Geneva’s biotech boom are straightforward. The Lake Geneva region, marketing itself as Switzerland’s ‘Health Valley’, houses over 750 life science companies. Switzerland’s biotech sector saw a 50% jump in capital investment in 2024, reaching over CHF 2 billion compared to CHF 1.4 billion in 2023.
That investment growth creates immediate demand. Companies need space to run experiments, house equipment and meet regulatory requirements. Traditional lab leases don’t match the speed biotech companies operate at – fundraising rounds can close in months, research pivots happen overnight and regulatory timelines don’t wait for property contracts.
‘Geneva is rising as one of the most active life science clusters in the world,’ said Xi Zhang, founder and CEO of Superlab Suisse. ‘With global institutions, cutting-edge research and a fast-growing biotech sector, Geneva is shaping the future of life sciences.’
The term ‘Lab-as-a-Service’ sounds like consulting speak, but the practical offering is straightforward. Superlab Suisse provides both private and shared lab spaces that are ready to use immediately. Companies get access to shared scientific equipment on demand, full operational support including biosafety and compliance handling, and waste management.
The business model also includes access to what the company calls a scientific and entrepreneurial network, plus preferential rates with lab suppliers through an integrated e-commerce platform. That last point matters more than it might initially appear – lab supply costs can quickly drain a startup’s runway, particularly when companies are buying small quantities without negotiating power.
Subscribe to our newsletter and never miss a story. No spam, ever.

The first crewed flight beyond Earth orbit in 53 years is not a landing. It is the test that decides whether a landing is possible.

An internal AI agent told a Meta engineer how to fix a problem. They followed the instructions without verifying them and it exposed sensitive data for two hours.

Denver artist Howard Harris holds a U.S. patent on a Techspressionist technique that layers sublimation-printed aluminum with acrylic grids to create photographs that shift with the viewer. Galleries in New York and Florence represent his work.
These facilities eliminate the capital expenditure and setup time that traditionally slow down biotech operations. Instead of months spent fitting out lab space and sourcing equipment, companies can focus on actual research and development.
Campus Biotech sits at the centre of Geneva’s research infrastructure. The facility houses institutional partners including EPFL, Université de Genève, the Wyss Center, HUG, FONGIT, Fondation Campus Biotech Geneva and Hepia. That concentration creates immediate networking opportunities and potential collaboration paths.
Campus Biotech is expanding its facilities to meet growing demand, with Building B4 adding nearly 8,800 square metres of laboratory and office space. The campus runs on 100% renewable energy from Lake Geneva and includes contemporary amenities designed to support startup operations.
The location gives companies access to Geneva’s broader life sciences infrastructure while avoiding the costs and complications of setting up independent facilities. For startups balancing research progress against cash runway calculations, that operational simplicity can make the difference between success and failure.
‘Geneva is rapidly becoming a global hub for life sciences, where research and new developments come together,’ said Igor Fisch, Chair of FONGIT and serial life sciences entrepreneur. ‘We’re proud to support Superlab Suisse’s expansion to Campus Biotech, providing startups with access to world-class infrastructure.’
The practical impact centres on three areas: speed to market, compliance ease and cost management. Companies can begin operations immediately rather than spending months on facility setup. Biosafety and regulatory compliance is handled by the facility rather than requiring internal expertise. Operating costs become predictable monthly expenses rather than large upfront investments.
Recent research shows more than one-third of biotechs have less than a year of cash remaining, making cost predictability and operational efficiency critical business factors rather than nice-to-have conveniences.
Superlab Suisse has international expansion underway in Europe, the US and Asia. That geographic spread raises questions about how the Lab-as-a-Service model transfers across different regulatory environments and market conditions.
Other players are testing similar approaches. Astellas recently opened its SakuLab-Tsukuba facility in Japan to support biotech startups, while various European markets are seeing shared laboratory concepts appear to address space shortages.
The success of these models will likely depend on how well they match local market needs and regulatory requirements. Geneva’s combination of research infrastructure, funding availability and regulatory environment creates specific conditions that may not replicate directly in other markets.
For founders and investors choosing where to base biotech operations in Switzerland or Europe, Geneva’s lab space options now include immediate-access facilities alongside traditional leasing arrangements. The choice between locations increasingly comes down to operational support rather than just cost and talent availability.
Speed and service may prove the real differentiators as biotech companies face pressure to demonstrate progress quickly to maintain funding. The Greater Geneva Bern area offers competitive tax regimes and flexible labour laws alongside the research infrastructure, creating a package that addresses multiple startup needs simultaneously.
Geneva’s lab space race has a new player, and the focus on operational simplicity shows broader industry pressure to reduce the time between scientific discovery and commercial development. Whether that translates into more successful biotechs or simply faster failures remains to be seen, but the infrastructure is now in place to find out.